1-20 of 132
Oliver G. Ottmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TKI vs relapse after HSCT: is the jury still out?

Oliver G. Ottmann
Journal: Blood
Blood (2020) 136 (15): 1705–1706.
https://doi.org/10.1182/blood.2020007021
Published: 2020
Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4055.
https://doi.org/10.1182/blood-2018-99-117257
Published: 2018
Journal Articles

Extracellular Microvesicle Cytokines Secreted from Bone Marrow Mesenchymal Cells Mediate Proliferative and Survival Advantage in Acute Myeloid Leukaemia

Michelle Lazenby, BSc, Oliver G. Ottmann, MD, Keith Wilson, FRCPath, MRCP, MBBS, Caroline Alvares, MBBS, PhD, Joanna Zabkiewicz, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2744.
https://doi.org/10.1182/blood-2018-99-113342
Published: 2018
Journal Articles

Adipogeneis in the Bone Marrow Microenvironment Confers a Proliferative Advantage in Residual Leukaemic Cell Populations in Acute Myeloid Leukaemia after Allogeneic Stem Cell Transplantation

Felicity May, BSc, Caroline Alvares, MBBS, PhD, Oliver G. Ottmann, MD, Joanna Zabkiewicz, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2580.
https://doi.org/10.1182/blood-2018-99-114443
Published: 2018
Journal Articles

Bone Marrow Stromal Cells Mediate Adhesion Based Drug Resistance in Acute Myeloid Leukaemia through Reciprocal Feedback of the β-Catenin/CD44 Signalling Axis

Lihui Zhuang, PhD MSc, BSc, Richard Darley, PhD, Oliver G. Ottmann, MD, Joanna Zabkiewicz, PhD, Caroline Alvares, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2776.
https://doi.org/10.1182/blood-2018-99-113811
Published: 2018
Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Anna G Turkina, Prof., MD, Olga Vinogradova, MD PhD, Elza Lomaia, MD, Evgeniya Shatokhina, MD PhD, Oleg Shukhov, MD PhD, Ekaterina Chelysheva, MD PhD, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, MD PhD, Nadia Siordia, MD, Dzhariyat Shikhbabaeva, Vasily Shuvaev, MD, Jorge E. Cortes, MD, Robert Peter Gale, Michele Baccarani, MD, Oliver G. Ottmann, MD, Ilya Mikhailov, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 790.
https://doi.org/10.1182/blood-2018-99-116803
Published: 2018
Journal Articles

Subtractive Interaction Proteomics Reveal a Network of Signaling Pathways Activated By an Oncogenic Transcription Factor in High Risk AML

Claudia Chiriches, PhD, Nathalie Guillen, PhD, Michal Rokicki, Carol Guy, Afsar Mian, PhD, Oliver G. Ottmann, MD, Martin Ruthardt
Journal: Blood
Blood (2018) 132 (Supplement 1): 3917.
https://doi.org/10.1182/blood-2018-99-116631
Published: 2018
Journal Articles

Nilotinib (Tasigna ® ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Oliver G. Ottmann, MD, Heike Pfeifer, MD, Jean-Michel Cayuela, PhD, Karsten Spiekermann, MD, Wolfram Jung, MD, Joachim Beck, Emmanuel Raffoux, MD, Pascal Turlure, MD, Chantal Himberlin, Francoise Huguet, MD, Andreas Viardot, MD, Knut Wendelin, MD, Albrecht Reichle, MD, Sébastien Maury, MD PhD, Laurence Sanhes, MD, Francoise Isnard, PhD, Jean-Yves Cahn, MD, Stephane Lepretre, Patrice Chevallier, MD, Martine Escoffre-Barbe, MD, Josep-Maria Ribera, MD PhD, Dieter Hoelzer, MD PhD, Nicola Goekbuget, MD, Hervé Dombret, Philippe Rousselot, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 31.
https://doi.org/10.1182/blood-2018-99-114552
Published: 2018
Journal Articles

Genomic CDKN2A/2B deletions in adult Ph + ALL are adverse despite allogeneic stem cell transplantation

Heike Pfeifer, Katharina Raum, Sandra Markovic, Verena Nowak, Stephanie Fey, Julia Obländer, Jovita Pressler, Verena Böhm, Monika Brüggemann, Lydia Wunderle, Andreas Hüttmann, Ralph Wäsch, Joachim Beck, Matthias Stelljes, Andreas Viardot, Fabian Lang, Dieter Hoelzer, Wolf-Karsten Hofmann, Hubert Serve, Christel Weiss, Nicola Goekbuget, Oliver G. Ottmann, Daniel Nowak
Journal: Blood
Blood (2018) 131 (13): 1464–1475.
https://doi.org/10.1182/blood-2017-07-796862
Published: 2018
Includes: Supplemental data
Journal Articles

CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells

Mateusz Legut, Garry Dolton, Afsar Ali Mian, Oliver G. Ottmann, Andrew K. Sewell
Journal: Blood
Blood (2018) 131 (3): 311–322.
https://doi.org/10.1182/blood-2017-05-787598
Published: 2018
Includes: Supplemental data
Journal Articles

A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease

Elsa Bernard, PhD, Kenichi Yoshida, MD PhD, Gunes Gundem, PhD, Jacob Grinfeld, MBChB, BSc, MRCP, FRCPath, Jyoti Nangalia, MBBChir, MA, MRCP, FRCPath, PhD, Daniel Leongamornlert, PhD, Noushin Farnoud, PhD, Juan Medina, Matahi Moarii, PhD, Charlie Massie, PhD, Yasunobu Nagata, MD PhD, Yusuke Okuno, MD PhD, Torsten Haferlach, MD, Seishi Ogawa, MD PhD, Amanda Gilkes, Oliver G. Ottmann, MD, Robert K. Hills, DPhil, Nigel H. Russell, Brian J.P Huntly, Anthony R Green, PhD FRCP, FRCPath, FMedSci, Alan K. Burnett, MD, Peter Campbell, PhD, Elli Papaemmanuil, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1414.
https://doi.org/10.1182/blood.V130.Suppl_1.1414.1414
Published: 2017
Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Yeow-Tee Goh, MBBS, MMed, Oliver G. Ottmann, MD, Hironobu Minami, MD PhD, Delphine Rea, MD PhD, Fabian Lang, MD, Michael J. Mauro, MD, Daniel J. DeAngelo, MD PhD, Moshe Talpaz, MD, Andreas Hochhaus, Prof. Dr., Massimo Breccia, MD, Jorge E. Cortes, MD, Michael C. Heinrich, MD, Jeroen Janssen, MD, Juan-Luis Steegmann, MD PhD, François-Xavier Mahon, MD PhD, Raina Duan, PhD, Varsha Iyer, David Hynds, MS, Gary J. Vanasse, MD, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2016) 128 (22): 625.
https://doi.org/10.1182/blood.V128.22.625.625
Published: 2016
Journal Articles

A Network of Activated Cancer Signaling Pathways in a High Risk Subgroup of Acute Myeloid Leukemia Targetable By SRC-Kinase Inhibitors

Claudia Chiriches, PhD, Dilawar Khan, PhD, Nathalie Guillen, PhD, Michal Rokicki, Carol Guy, Afsar Mian, PhD, Oliver G. Ottmann, MD, Martin Ruthardt, MD
Journal: Blood
Blood (2016) 128 (22): 2746.
https://doi.org/10.1182/blood.V128.22.2746.2746
Published: 2016
Journal Articles

Axl/ Mer Inhibitor ONO-9330547 As a Novel Therapeutic Agent in a Stromal Co-Culture Model of Primary Acute Myeloid Leukaemia (AML)

Marie Gilmour, PhD, Anna Scholtz, Oliver G. Ottmann, MD, Robert K Hills, DPhil, Steven Knapper, Joanna Zabkiewicz, PhD
Journal: Blood
Blood (2016) 128 (22): 2754.
https://doi.org/10.1182/blood.V128.22.2754.2754
Published: 2016
Journal Articles

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Monika Haubitz, PhD, Elisabeth Oppliger Leibundgut, PharmD, Ingrid Helsen, Dania Hiltbrunner, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Röth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD
Journal: Blood
Blood (2016) 128 (22): 1938.
https://doi.org/10.1182/blood.V128.22.1938.1938
Published: 2016
Journal Articles

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Clinical Trials & Observations
Philippe Rousselot, Marie Magdelaine Coudé, Nicola Gokbuget, Carlo Gambacorti Passerini, Sandrine Hayette, Jean-Michel Cayuela, Françoise Huguet, Thibaut Leguay, Patrice Chevallier, Celia Salanoubat, Caroline Bonmati, Magda Alexis, Mathilde Hunault, Sylvie Glaisner, Philippe Agape, Christian Berthou, Eric Jourdan, José Fernandes, Laurent Sutton, Anne Banos, Oumedaly Reman, Bruno Lioure, Xavier Thomas, Norbert Ifrah, Marina Lafage-Pochitaloff, Anne Bornand, Laure Morisset, Valérie Robin, Heike Pfeifer, Andre Delannoy, Josep Ribera, Renato Bassan, Marc Delord, Dieter Hoelzer, Herve Dombret, Oliver G. Ottmann
Journal: Blood
Blood (2016) 128 (6): 774–782.
https://doi.org/10.1182/blood-2016-02-700153
Published: 2016
Includes: Supplemental data
Journal Articles

Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study

Guillermo Garcia-Manero, MD, Mikkael A. Sekeres, MD MS, Miklos Egyed, MDPhD Prof., Giuliana Alimena, MD, Carlos Graux, Jamie D. Cavenagh, MD, Huda Salman, Arpad Illes, MD PhD, Pierre Fenaux, MD PhD, Daniel J. DeAngelo, Reinhard Stauder, MD MSc, Karen Yee, MD, Nancy Y Zhu, MDFRCPC, Je-Hwan Lee, MD PhD, David Valcarcel, MD PhD, Alan MacWhannell, Zita Borbenyi, MD PhD, Antje Wegener, Lucien Gazi, Suddhasatta Acharyya, PhD, Florence Binlich, Oliver G. Ottmann, MD
Journal: Blood
Blood (2015) 126 (23): 2861.
https://doi.org/10.1182/blood.V126.23.2861.2861
Published: 2015
Journal Articles

Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial

Gesine Bug, MD, Andreas Burchert, MD, Eva-Maria Wagner, MD, Nicolaus Kroeger, MD, Zuzana Jedlickova, MD, Saskia Gueller, MD, Stephan Metzelder, MD, Andrea Wolf, Peter Bader, MD, Sabine Huenecke, PhD, Hubert Serve, Oliver G. Ottmann, MD
Journal: Blood
Blood (2015) 126 (23): 4344.
https://doi.org/10.1182/blood.V126.23.4344.4344
Published: 2015
Journal Articles

Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)

Giovanni Martinelli, MD, Hervé Dombret, Patrice Chevallier, MD PhD, Oliver G. Ottmann, MD, Nicola Goekbuget, MD, Max S. Topp, MD, Adele K. Fielding, MB BS, PhD, Lulu Ren Sterling, PhD, Jonathan Benjamin, MD, Anthony Selwyn Stein, MD
Journal: Blood
Blood (2015) 126 (23): 679.
https://doi.org/10.1182/blood.V126.23.679.679
Published: 2015
Journal Articles

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Elisabeth Oppliger Leibundgut, PharmD, Monika Haubitz, PhD, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Roeth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD
Journal: Blood
Blood (2015) 126 (23): 57.
https://doi.org/10.1182/blood.V126.23.57.57
Published: 2015